Unknown NA INTERVENTIONAL 2-arm NCT05370898

The Study of Chinese Medicine for the Treatment of Primary Osteoporosis

Clinical Study of Bugu Shengsui Decoction for the Treatment of Primary Osteoporosis (Kidney Yang Deficiency Syndrome)

Sponsor: Wangjing Hospital, China Academy of Chinese Medical Sciences

Interventions Caltrate D Chinese medicine prescription Placebo

Updated 4 times since 2022 Last updated: May 17, 2022 Started: Jul 1, 2022 Primary completion: Dec 1, 2022 Completion: May 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Primary Osteoporosis, this trial is ongoing. The trial is conducted by Wangjing Hospital, China Academy of Chinese Medical Sciences and has accumulated 4 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jun 2024 — Jul 2024 [monthly]

Unknown Status NA

Status: Not Yet Recruiting → Unknown Status
Jun 2022 — Jun 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Data source: Wangjing Hospital, China Academy of Chinese Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China